The list includes 52 branded drugs from more than 30 different drugmakers, including Novartis, GlaxoSmithKline and Gilead Sciences. The agency believes these drug companies may be blocking generic drugmakers’ access to the branded drug samples they need to bring their own cheaper versions to the market.
“No patients should be priced out of medicines they need to support their health,” said FDA Commissioner Scott Gottlieb, MD. “We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval.”
The FDA published the list as part of its Drug Competition Action Plan, which the agency rolled out last spring.
More articles on supply chain:
Vermont first state to legalize drug importation from Canada
Janssen, Pharmacyclics cancel plan to triple cost of cancer drug after backlash
6 key proposals unveiled in Trump’s plan to combat rising drug costs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
